Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 price objective on the biotechnology company’s stock. Other analysts have also issued research reports about the company. B. Riley decreased their price […]

Related Keywords

California ,United States ,Canada , ,News Ratings For Actinium Pharmaceuticals Daily ,Maxim Group ,Actinium Pharmaceuticals Stock Performance ,Deutsche Bank ,Actinium Pharmaceuticals Company Profile ,Actinium Pharmaceuticals ,Manufacturers Life Insurance Company ,Royal Bank ,Institutional Trading Of Actinium Pharmaceuticals ,Actinium Pharmaceuticals Inc ,Free Report ,Moderate Buy ,State Teachers Retirement System ,Get Free Report ,Actinium Pharmaceuticals Daily ,Nyseamerican Atnm ,Atnm ,Medical ,Reiterated Rating ,Hc Wainwright ,